HCA Healthcare (HCA) has just been removed from several major Russell growth indexes after the latest rebalancing, a technical shift that primarily affects who owns the stock rather than how its hospitals operate.

Index removals have come after a period where HCA Healthcare’s share price return has fallen 16.4% year to date and 16.7% over three months, even as its 5 year total shareholder return of 89.04% points to a much stronger longer run record.

If you are reassessing your healthcare exposure after HCA Healthcare’s index changes, this could be a good moment to look at other opportunities in AI driven medicine. You can do this through our screener of 39 healthcare AI stocks

So, with HCA Healthcare now trading after a double digit year to date decline but screening as undervalued on both DCF and P/E, are you looking at a genuine opportunity, or is the market already factoring in future growth?

Most Popular Narrative: 37.5% Undervalued

According to the most followed narrative on HCA Healthcare, a fair value of $629.14 sits well above the recent close of $393.24. This creates a wide gap that long term investors will want to understand before reacting to the index removal.

In a market that often swings between hype and fear, HCA Healthcare (NYSE: HCA) stands out for a different reason: consistency. While much of the healthcare sector wrestles with reimbursement uncertainty, labor costs, and regulatory noise, HCA continues to operate from a position of scale and operational discipline. It is not flashy, but it is effective.

The fair value story here leans heavily on HCA Healthcare turning its scale, steady earnings growth and resilient margins into sustained cash generation and a valuation multiple more often associated with faster growing sectors. Curious which growth and margin assumptions sit underneath that $629.14 figure and how they connect back to today’s $393.24 price point? The full narrative lays out those building blocks in plain language so you can judge the gap for yourself.

Result: Fair Value of $629.14 (UNDERVALUED)

However, HCA Healthcare’s reliance on U.S. reimbursement frameworks and ongoing labor cost pressures could both tighten margins and weaken the case for a higher valuation multiple.

Next Steps

The mixed tone around HCA Healthcare, with both concerns and optimism in play, makes this a moment to move quickly and review the evidence yourself, then weigh up the 5 key rewards and 2 important warning signs.

Looking for more investment ideas beyond HCA Healthcare?

If HCA Healthcare has you rethinking where to focus next, use this moment to scan fresh opportunities that fit your goals before the crowd catches on.

• Target companies that combine quality with attractive pricing by checking out our screen of 41 high quality undervalued stocks that may merit a closer look.
• Strengthen the defensive side of your portfolio by reviewing the solid balance sheet and fundamentals stocks screener (47 results) and see which stocks match your comfort on financial resilience.
• Look for lesser known opportunities through the screener containing 19 high quality undiscovered gems before they draw wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.